A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
#1PRI RANKED
Most Cited Paper
in Receptor Mechanisms and Signaling
18 Months Post-Publication
Class of 2026
“A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
AMG 133 · AMG 133 · GIPR antagonist · GLP-1 receptor agonist · bispecific molecule · anti-human GIPR monoclonal antibody · GLP-1 receptor agonist · incretin receptors · body weight reduction · metabolic markers · obese mice · cynomolgus monkeys · phase 1 clinical trial · dose-dependent weight loss · multiple ascending dose · obesity · amino acid linkers · NCT04478708
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Receptor Mechanisms and Signaling Papers, Class of 2026. https://pri.pepkio.com/top-papers/receptor-mechanisms-and-signaling/2026. Accessed 2026-07-29. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459